SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
+5.1%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$571M
AUM Growth
+$571M
(+8.4%)
Cap. Flow
+$42.2M
Cap. Flow
% of AUM
7.39%
Top 10 Holdings %
Top 10 Hldgs %
59.5%
Holding
28
New
2
Increased
16
Reduced
8
Closed
1
Top Buys
| 1 |
Gilead Sciences
GILD
|
$27M |
| 2 |
Bristol-Myers Squibb
BMY
|
$22.1M |
| 3 |
Abbott
ABT
|
$17.4M |
| 4 |
LPNT
LifePoint Health, Inc.
LPNT
|
$9.97M |
| 5 |
McKesson
MCK
|
$7.08M |
Top Sells
| 1 |
STJ
St Jude Medical
STJ
|
$20.1M |
| 2 |
SHPG
Shire pic
SHPG
|
$11.5M |
| 3 |
Biogen
BIIB
|
$7.48M |
| 4 |
Eli Lilly
LLY
|
$6.68M |
| 5 |
Exelixis
EXEL
|
$5.55M |
Sector Composition
| 1 | Healthcare | 98.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$657B
| $60.9M | 10.66% |
824,450
-90,470
| -10% | -$6.68M |
|
2
Baxter International
BAX
$12.7B
| $51.4M | 9% |
1,079,233
+290
| +0% | +$13.8K |
|
|
3
Abbott
ABT
$231B
| $34.8M | 6.09% |
872,590
+436,390
| +100% | +$17.4M |
|
|
4
Bristol-Myers Squibb
BMY
$96B
| $32M | 5.6% |
608,190
+420,690
| +224% | +$22.1M |
|
5
Revvity
RVTY
$10.5B
| $31.9M | 5.59% |
615,428
+71,718
| +13% | +$3.72M |
|
6
Ironwood Pharmaceuticals
IRWD
$214M
| $27.8M | 4.87% |
1,960,548
+191,180
| +11% | +$2.71M |
|
7
Boston Scientific
BSX
$156B
| $27.7M | 4.84% |
1,254,880
-157,290
| -11% | -$3.47M |
|
|
8
Gilead Sciences
GILD
$140B
| $27M | 4.73% |
+364,990
| New | +$27M |
|
9
Integra LifeSciences
IART
$1.18B
| $24M | 4.2% |
306,207
-23,450
| -7% | -$1.84M |
|
10
Vertex Pharmaceuticals
VRTX
$100B
| $22.4M | 3.92% |
268,880
-10,203
| -4% | -$849K |
|
11
Bio-Rad Laboratories Class A
BIO
$8.06B
| $22.4M | 3.91% |
132,584
+3,460
| +3% | +$583K |
|
12
Masimo
MASI
$7.59B
| $21.5M | 3.77% |
356,223
+4,170
| +1% | +$252K |
|
|
13
Biogen
BIIB
$19.4B
| $21.1M | 3.7% |
71,400
-25,290
| -26% | -$7.48M |
|
|
14
Exelixis
EXEL
$10.1B
| $19.9M | 3.48% |
1,610,491
-449,342
| -22% | -$5.55M |
|
15
Merck
MRK
$210B
| $19.1M | 3.34% |
318,010
+70,360
| +28% | +$4.23M |
|
|
16
McKesson
MCK
$85.4B
| $17.7M | 3.1% |
131,660
+52,640
| +67% | +$7.08M |
|
|
PDCO
17
DELISTED
Patterson Companies, Inc.
PDCO
| $16.1M | 2.83% |
345,792
-71,052
| -17% | -$3.32M |
|
18
Elevance Health
ELV
$71.8B
| $15.2M | 2.66% |
122,850
+18,550
| +18% | +$2.29M |
|
|
SHPG
19
DELISTED
Shire pic
SHPG
| $14.2M | 2.49% |
84,461
-67,925
| -45% | -$11.5M |
|
20
Cigna
CI
$80.3B
| $14.1M | 2.48% |
112,070
+2,200
| +2% | +$278K |
|
|
MNTA
21
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $10.6M | 1.86% |
958,879
+43,900
| +5% | +$487K |
|
22
United Therapeutics
UTHR
$13.8B
| $9.98M | 1.75% |
83,474
+2,250
| +3% | +$269K |
|
|
LPNT
23
DELISTED
LifePoint Health, Inc.
LPNT
| $9.97M | 1.75% |
+164,714
| New | +$9.97M |
|
|
IPXL
24
DELISTED
Impax Laboratories, Inc.
IPXL
| $7.32M | 1.28% |
409,964
+176,030
| +75% | +$3.14M |
|
25
Owens & Minor
OMI
$378M
| $6.75M | 1.18% |
211,172
+8,830
| +4% | +$282K |
|